Clinical effects of CD45 on the prognosis of extramedullary myeloma relapse

Abstract

Despite advances in multiple myeloma (MM) therapy in recent years, virtually all patients eventually relapse, 1-4 and extramedullary relapse (EMR) remains a challenge. The incidence of EMR arising during the clinical course of MM has increased in recent years. 5,6 EMR in MM patients indicates an aggressive/advanced disease as well as a poor prognosis. Flow cytometry is widely used in the diagnosis and monitoring of haematological disorders, and a flow cytometric analysis of

A multi-omic approach reveals utility of CD45 expression in prognosis and novel target discovery

“…Many studies have found that the abundance of tumor-infiltrating cells is associated with patient prognosis ( Gentles et al, 2015 ; Wang et al, 2019 ; Chen et al, 2020 ). In addition, some studies have reported that CD45 has prognostic significance in tumor ( Behm et al, 1992 ; Ishizawa et al, 2019 ; Oka et al, 2020 ; Balasubramanian et al, 2021 ). We think that combining CD45 expression with infiltration of specific immune cells may improve the accuracy of predicting patient prognosis and its potential clinical applications.…”

Advances in Biomarkers for Multiple Myeloma

“…A study has found a correlation between the expression of CD45 in tumor plasma cells of patients with extramedullary recurrence of MM and the prognosis of these patients, irrespective of other prognostic factors. Therapeutic strategies need to be established for patients with extramedullary recurrence and CD45-MM cells to ameliorate adverse outcomes [20] .…”